Design and development of novel EGFR inhibitors spanning all subgroups of EGFR mutations in non-small cell lung cancer
{{output}}
EGFR mutations are common in non-small cell lung cancer (NSCLC), with classical mutations (L858R and exon 19 deletions [Ex19del]) and T790M mutation responsive to three generations of EGFR inhibitors (TKIs). However, the other 30% EGFR mutations, which are cla... ...
